Research Tools

This report provides an overview of the cell therapy R&D and manufacturing market, from 2023-2028. The cell therapy market, as defined in this report, is comprised of revenue from instruments, consumables, and software sold to academic, clinical, biopharma, CDMO and CRO customers, along with service revenues generated by CDMOs and CROs.

DeciBio conducted 12 interviews with U.S. clinicians and healthcare professionals to understand how blood-based EDx testing is being clinically adopted, to identify key regulatory and commercial barriers to broader use, to define the excitement around single and multi-cancer early detection (MCED) tests, and to collect vendor feedback from current users.

DeciBio conducted 9 interviews with experts at top Academic Medical Centers (AMC) and top biopharma stakeholders to better understand their perceptions and use of real-world data (RWD) at their organizations, as well as key RWD unmet needs and vendor perceptions.

DecBio conducted 10 interviews with clinical oncologists and KOLs at top biopharma to better understand their definitions and use of comprehensive genomic profiling (CGP) in the diagnosis and treatment of solid tumors, as well as key CGP pain points and vendor perceptions.